Tandem Diabetes Care is caught between two competing forces this week — short sellers keep reducing exposure, yet the stock has given back nearly 9% over the past five sessions to close at $21.58.
The short-covering trend noted in our August 22 note has continued. Short interest dropped a further 4% on Tuesday alone, bringing the total down to 10.34 million shares, or 15.2% of the free float — down from roughly 13 million at the start of August. That is still an elevated level in absolute terms, but the direction has been consistent for three weeks. Borrow conditions reinforce the picture: cost to borrow is only 0.54%, barely changed from recent sessions, and availability has actually loosened further to over 1,130% — more than eleven shares available for every one currently lent out. There is no mechanical pressure forcing covers here. The ORTEX short score has drifted down to 55.6 from 57.2 ten days ago, a modest but consistent move in the same direction. Options are not flashing alarm either: the put/call ratio is 0.51, only fractionally above its 20-day average of 0.47, and well within one standard deviation of normal — call activity is holding its own despite the weekly pullback.
The Street's message is broadly constructive but not without friction. William Blair initiated coverage with an Outperform rating this week, adding to an 11-analyst buy consensus — a rare clean sweep with no sell ratings in the dataset. But the price-target picture is messier. After the August 6 earnings beat — which sent the stock up 14% in a single session — RBC Capital actually trimmed its target from $30 to $26, even while maintaining Outperform. Citigroup moved the other way, lifting its Neutral target from $17 to $21 after the print. The net read is that bulls believe the pharmacy-channel strategy and the Mobi Tubeless pump justify a re-rating, while bears point to GLP-1 headwinds on insulin delivery demand and a product line that remains narrowly concentrated. The company is not yet profitable — EV/EBITDA is running at 18.5x on a business with a negative earnings yield — so execution against the growth roadmap carries real weight. The analyst recommendation divergence factor score ranks in the 93rd percentile, meaning the buy-heavy consensus is unusually lopsided relative to the broader universe.
Institutional holders have been adding, not trimming. BlackRock reported a position of 11.6 million shares as of July 31, up roughly 892,000 shares on the period. First Light Asset Management made a more aggressive move, adding over 2 million shares to reach 3.4 million — a meaningful commitment for a smaller active manager. Sessa Capital and Vanguard also added on the quarter. Insider activity on August 14 was routine: a cluster of C-suite sells at $22.72, all small in dollar terms (none exceeded $25,000) and accompanied by award grants. Net insider activity over 90 days is slightly positive at $378,000 but at a scale that carries little signal.
The closest peer context is mixed. DXCM slipped 2.1% on the day and is down fractionally on the week — broadly in line with TNDM's daily move. ICUI and AORT are also softer, the latter down nearly 9% on the week, suggesting some sector-level softness rather than a purely TNDM-specific pull. SENS bucked the trend, gaining 9.6% on the week, a reminder that company-specific catalysts still dominate in this space.
With the next earnings date pencilled in for November 4, the focal point over the coming weeks is whether the post-August-6 momentum — which added roughly 26% to the stock over one month — can find a floor here, or whether the short covering that has propped the narrative will slow as bears run out of easy exits.
See the live data behind this article on ORTEX.
Open TNDM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
